Table 1.

Study population characteristics at baseline.

Patient Characteristics
Age, years, median [IQR]	44 [34–51]
Race, n (%)
Caucasian	33 (43%)
African American	41 (53%)
Other	3 (4%)
Female gender, n (%)	74 (96%)
≥ College education, n (%)	46 (60%)
Married or cohabiting, n (%)	34 (45%)
Annual Income >$100,000, n (%)	12 (16%)
Disability, n (%)	28 (36%)
Insurance, n (%)
Medicaid	12 (16%)
Medicare	23 (30%)
Private	39 (51%)
Other	3 (4%)
SLE duration, years, median [IQR]	15 [8–22]
No. prescribed SLE medications, median [IQR]	2 [1–3]
SLE Medications, n (%)
Hydroxychloroquine	68 (88%)
DMARDs	50 (65%)
Mycophenolate mofetil	28 (36%)
Azathioprine	11 (14%)
Methotrexate	12 (16%)
Leflunomide	3 (4%)
Belimumab	4 (5%)

IQR: Interquartile range; SLE: Systemic Lupus Erythematosus; DMARD: Disease Modifying Anti-Rheumatic Drug